Indeed, BIWA-4 (bivatuzumab), an anti-CD44 antibody, is currently in preclinical trials for patients with head and neck tumors, indicating the interest in CD44 inhibition as a potential cancer therapy [58]. Here, CD44 is linked to head and neck neoplasm.